Datamonitor, Dec 2010, Pages: 128
OUTLOOK TO 2015KEY FINDINGS
Overview of Biotech to
Biotech prescription pharma sales performance, 2003–
Biotech landscape, 2009–
Biotech company analysis
Biotech launch/core/expiry
Biophoenix Limited, Feb 2009, Pages: 312
modulators in cancer, CNS diseases, and chronic inflammation/autoimmunity. - Gain up-to-date competitive intelligence on apoptosis-modulating pipelines and identify the most promising drugs under development
Global Industry Analysts, Inc., Jan 2011, Pages: 804
Market AnalysisGrowth Drivers in a Capsule
Developed World: The Key Markets
Looking Ahead
Emerging Markets: The Future Growth Area
Competitive Scenario
World’s Leading Producers
Table 1: Leading
Global Industry Analysts, Inc., Feb 2010, Pages: 824
- A Mid- to Long-term Threat II-10
Year of Expected Generic Market Entry of Leading Biologics
in Rheumatoid Arthritis Therapy II-10
CompetitiveLandscape II-10
Table 6: Comparative Analysis of Leading
Decision Resources, Inc., Aug 2006, Pages: 30
landscape is changing—big pharma is moving in, competition is increasing, business strategies are proving inadequate, and pricing/reimbursement issues are increasingly vexing.
Get the Answers You Need
Global Industry Analysts, Inc., July 2009, Pages: 1810
III-83
A.Market Analysis III-83
Current and Future Analysis III-83
Generics Promotion in Japan III-83
Ageing Population - A Prime Target III-83
CompetitiveLandscape III-84
Table 51: Leading
Arrowhead Publishers, Dec 2006, Pages: 348
by Therapeutic Category
6.4.2.1 Cancer
6.4.2.2 Autoimmune/Inflammatory
6.4.3 Market Share by Country/Region
6.4.4 Key Product Sales
6.4.5 Market Share by Company
6.4.6 Market Outlook
6.4.6.1 Drivers
6
Global Industry Analysts, Inc., Aug 2011, Pages: 1305
as the fastest growing market with a CAGR of 28% over the analysis period. A key factor fueling market growth in Asia is the ever-growing information technology industry in the region. The biomarker technologies
